An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease - ATB200-04

Amicus Therapeutics Inc.0 sites25 target enrollmentJuly 7, 2023

Conditionsate-onset Pompe disease MedDRA version: 20.0Level: SOCClassification code: 10010331Term: Congenital familial and genetic disorders Class: 21 Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: ate-onset Pompe disease
Sponsor: Amicus Therapeutics Inc.
Enrollment: 25
Status: Active, not recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 7, 2023

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Amicus Therapeutics Inc.

Eligibility Criteria

Inclusion Criteria

•1\. (Cohort 1\) Male or female subjects (ERT\-naïve \[have never received a dose of rhGAA] or ERT\-experienced \[have received rhGAA for at least 6 months immediately before enrollment, and if ERT dosage has been modified, must have been on the modified dosage for at least 3 months before enrollment]) diagnosed with LOPD who are aged 12 to \< 18 years at screening., 2\. (Cohort 1\) Subject weighs \= 115 kg., 3\. (Cohort 1\) Subject has a sitting forced vital capacity (FVC) \= 30% of the predicted value for healthy adolescents (Global Lung Function Initiative) at screening, 4\. (Cohort 1\) Subject performs one 6\-Minute Walk Test (6MWT) (\= 75 meters) at screening that is valid, as determined by the clinical evaluator, 5\. (Cohort 2\) Male or female subjects (ERT\-naïve \[have never received a dose of rhGAA] or ERT\-experienced \[have received rhGAA for at least 6 months immediately before enrollment, and if ERT dosage has been modified, must have been on the modified dosage for at least 3 months before enrollment]) diagnosed with LOPD who are aged 0 months to \< 12 years at screening, 6\. (Cohort 2\) Subjects aged \= 5 to \< 12 years who perform one 6MWT (\= 40 meters) at screening that is valid, as determined by the clinical evaluator, 7\. (Cohort 1 \& 2\) Subject’s parent or legally authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of personal health information or research\-related health information, and subject provides assent, if applicable, based on site and local regulations., 8\. (Cohort 1 \& 2\) Subject must have a diagnosis of LOPD based on documentation of at least one of the following: a. deficiency of GAA enzyme b. gene encoding human acid a\-glucosidase (GAA) genotyping, 9\. (Cohort 1 \& 2\) If of reproductive potential and if sexually active, female and male subjects agree to use a highly effective method of contraception throughout the duration of the study and for up to 90 days after their last dose of cipaglucosidase alfa/miglustat

Exclusion Criteria

•1\. (Cohort 1 \& 2\) Subject has received any investigational/experimental drug, oral anabolic steroid or derivative, biologic, or device within 30 days or 5 half\-lives of the therapy or treatment, whichever is longer, before screening, 8\. (Cohort 1 \& 2\) Subject has moderate to severe hypertrophic cardiomyopathy aligning with classic IOPD, 9\. (Cohort 1 \& 2\) In the opinion of the investigator, the parent or legally authorized representative is unlikely or unable to comply with the study requirements, 12\. (Cohort 1 \& 2\) Subject has been placed in an institution by court or official order., 10\. (Cohort 1 \& 2\) Subject has any prior history of illness or condition known to affect motor function, such as, but not limited to, Guillain\-Barre syndrome, cerebral palsy, etc, 11\. (Cohort 2\) Subject who is diagnosed with Pompe disease via newborn screening and is asymptomatic (ie, showing no signs and symptoms of Pompe disease, 2\. (Cohort 1 \& 2\) Subject has received treatment with prohibited medications within 30 days of screening, 3\. (Cohort 1 \& 2\) Subject has received any gene therapy at any time, 4\. (Cohort 1 \& 2\) Subject has any intercurrent illness or condition at screening or baseline that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator and/or the medical monitor that the potential subject may have an unacceptable risk by participating in this study, 5\. (Cohort 1 \& 2\) Subject has a hypersensitivity to any of the excipients in cipaglucosidase alfa, approved rhGAA, or miglustat, 6\. (Cohort 1 \& 2\) Female subject is pregnant or breast\-feeding at screening, 7\. (Cohort 1 \& 2\) Subject requires the use of ventilation support for \> 6 hours per day while awake